FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320121061> ?p ?o ?g. }

• W2320121061 endingPage "539" @default.
• W2320121061 startingPage "539.1" @default.
• W2320121061 abstract "<h3>Background</h3> Rituximab (MabThera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients. There clearly is off-label use of this medication in practice in Europe, but the extent of it has not previously been analyzed. The International Registry for Biologics in SLE (IRBIS), initiated by the SLICC group provided the data for this study. <h3>Objectives</h3> To estimate the proportion of SLE patients treated with RTX in Europe. <h3>Methods</h3> Data previously submitted to the IRBIS registry by 28 centers in 11 European countries were complemented with additional clinical information from the participating sites and SLE prevalence estimates based on previously published data and data provided by direct contact with participating physicians. For the remaining countries in the European Union (EU) and European Economic Area-European Free Trade Association (EEA-EFTA), estimates were extrapolated on the assumption of regional similarities between countries. <h3>Results</h3> Most of the SLE-dedicated rheumatology specialty centers represented in this study had 200 to 300 SLE patients of whom generally <5% were treated with RTX. In the 11 European countries and regions represented in this report the estimated calculated rate of exposure to RTX among SLE patients ranged from 0.6-1.6%. Extrapolating to all 30 EU-EEA-EFTA countries, with an overall population of around 416 million, and with published prevalence estimates for SLE between 3.6 and 7.3 per 10.000 adults, we calculated that between 0.5 and 1.3% of European patients with SLE currently have been treated, off-label, with RTX. <h3>Conclusions</h3> In Europe, RTX is estimated to be used off-label in 0.5-1.3% of SLE patients. This modest number suggests that it is chosen only for those patients in whom established therapeutic options have been exhausted. Limitations of the study include the use of extrapolations, and the fact that RTX use by non-rheumatologists was not ascertained. Although controlled evidence for the efficacy of RTX in SLE is lacking, the current usage of RTX in SLE may be considered conservative, given the high medical need in the larger SLE patient population. <b>Supported by a research grant from Roche</b> <h3>Disclosure of Interest</h3> None Declared" @default.
• W2320121061 created "2016-06-24" @default.
• W2320121061 creator A5001878991 @default.
• W2320121061 creator A5015160683 @default.
• W2320121061 creator A5027317477 @default.
• W2320121061 creator A5038276560 @default.
• W2320121061 creator A5039265980 @default.
• W2320121061 creator A5047733120 @default.
• W2320121061 creator A5052911433 @default.
• W2320121061 creator A5064382938 @default.
• W2320121061 creator A5065798696 @default.
• W2320121061 creator A5066368809 @default.
• W2320121061 creator A5077488939 @default.
• W2320121061 creator A5084645574 @default.
• W2320121061 creator A5086942556 @default.
• W2320121061 creator A5089843291 @default.
• W2320121061 date "2013-06-01" @default.
• W2320121061 modified "2023-10-18" @default.
• W2320121061 title "SAT0199 An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries" @default.
• W2320121061 doi "https://doi.org/10.1136/annrheumdis-2012-eular.3146" @default.
• W2320121061 hasPublicationYear "2013" @default.
• W2320121061 type Work @default.
• W2320121061 sameAs 2320121061 @default.
• W2320121061 citedByCount "1" @default.
• W2320121061 countsByYear W23201210612013 @default.
• W2320121061 crossrefType "journal-article" @default.
• W2320121061 hasAuthorship W2320121061A5001878991 @default.
• W2320121061 hasAuthorship W2320121061A5015160683 @default.
• W2320121061 hasAuthorship W2320121061A5027317477 @default.
• W2320121061 hasAuthorship W2320121061A5038276560 @default.
• W2320121061 hasAuthorship W2320121061A5039265980 @default.
• W2320121061 hasAuthorship W2320121061A5047733120 @default.
• W2320121061 hasAuthorship W2320121061A5052911433 @default.
• W2320121061 hasAuthorship W2320121061A5064382938 @default.
• W2320121061 hasAuthorship W2320121061A5065798696 @default.
• W2320121061 hasAuthorship W2320121061A5066368809 @default.
• W2320121061 hasAuthorship W2320121061A5077488939 @default.
• W2320121061 hasAuthorship W2320121061A5084645574 @default.
• W2320121061 hasAuthorship W2320121061A5086942556 @default.
• W2320121061 hasAuthorship W2320121061A5089843291 @default.
• W2320121061 hasConcept C105639569 @default.
• W2320121061 hasConcept C126322002 @default.
• W2320121061 hasConcept C144024400 @default.
• W2320121061 hasConcept C144133560 @default.
• W2320121061 hasConcept C149923435 @default.
• W2320121061 hasConcept C187212893 @default.
• W2320121061 hasConcept C198451711 @default.
• W2320121061 hasConcept C2779338263 @default.
• W2320121061 hasConcept C2780653079 @default.
• W2320121061 hasConcept C2908647359 @default.
• W2320121061 hasConcept C2910001868 @default.
• W2320121061 hasConcept C512399662 @default.
• W2320121061 hasConcept C71924100 @default.
• W2320121061 hasConcept C99454951 @default.
• W2320121061 hasConceptScore W2320121061C105639569 @default.
• W2320121061 hasConceptScore W2320121061C126322002 @default.
• W2320121061 hasConceptScore W2320121061C144024400 @default.
• W2320121061 hasConceptScore W2320121061C144133560 @default.
• W2320121061 hasConceptScore W2320121061C149923435 @default.
• W2320121061 hasConceptScore W2320121061C187212893 @default.
• W2320121061 hasConceptScore W2320121061C198451711 @default.
• W2320121061 hasConceptScore W2320121061C2779338263 @default.
• W2320121061 hasConceptScore W2320121061C2780653079 @default.
• W2320121061 hasConceptScore W2320121061C2908647359 @default.
• W2320121061 hasConceptScore W2320121061C2910001868 @default.
• W2320121061 hasConceptScore W2320121061C512399662 @default.
• W2320121061 hasConceptScore W2320121061C71924100 @default.
• W2320121061 hasConceptScore W2320121061C99454951 @default.
• W2320121061 hasIssue "Suppl 3" @default.
• W2320121061 hasLocation W23201210611 @default.
• W2320121061 hasOpenAccess W2320121061 @default.
• W2320121061 hasPrimaryLocation W23201210611 @default.
• W2320121061 hasRelatedWork W1998212570 @default.
• W2320121061 hasRelatedWork W2097023213 @default.
• W2320121061 hasRelatedWork W2143803333 @default.
• W2320121061 hasRelatedWork W2416990542 @default.
• W2320121061 hasRelatedWork W2584442866 @default.
• W2320121061 hasRelatedWork W2593921835 @default.
• W2320121061 hasRelatedWork W2622204852 @default.
• W2320121061 hasRelatedWork W2805808559 @default.
• W2320121061 hasRelatedWork W2972302572 @default.
• W2320121061 hasRelatedWork W4255039225 @default.
• W2320121061 hasVolume "71" @default.
• W2320121061 isParatext "false" @default.
• W2320121061 isRetracted "false" @default.
• W2320121061 magId "2320121061" @default.
• W2320121061 workType "article" @default.